Clinical Trials Browser

INDUSTRY × tocilizumab × 1 year × Clear all

NCT04246086 2026-03-19

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06934044 2026-03-16

A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT05583617 2026-03-06

PLYCOM

Phase 1/2 Recruiting

Multiple Myeloma

NCT03075696 2026-03-05

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Phase 1/2 Recruiting

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT05207670 2026-03-05

MorningSun

Phase 2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT06624085 2026-03-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

Lymphoma

NCT05091424 2026-03-03

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06084936 2026-03-03

GLOBRYTE

Phase 3 Recruiting

Lymphoma

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT03448042 2026-02-27

A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Phase 1 Active not recruiting

Other solid neoplasm

Solid Tumors

NCT04524871 2026-02-27

MORPHEUS-LIVER

Phase 1/2 Recruiting

Advanced Liver Cancers

NCT05169515 2026-02-23

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

Lymphoma, Non-Hodgkin

NCT05646836 2026-02-17

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT05535244 2026-02-09

CAMMA 2

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT03275103 2026-02-05

Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Completed

Multiple Myeloma

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT04408638 2026-01-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03533283 2026-01-06

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin

NCT04910568 2025-12-24

CAMMA 1

Phase 1 Active not recruiting

Multiple Myeloma

NCT03337698 2025-12-12

Morpheus Lung

Phase 1/2 Completed

Carcinoma, Non-Small-Cell Lung

NCT03564340 2025-12-03

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT05364424 2025-12-01

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

Phase 1 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Phase 1/2 Completed

341 enrolled 28 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03677154 2025-08-21

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

Lymphoma, Large B-Cell, Diffuse